Video
Dr. Gupta on Challenges With Perioperative Immunotherapy in Bladder Cancers
Author(s):
Shilpa Gupta, MD, discusses challenges with perioperative immunotherapy in bladder cancer.
Shilpa Gupta, MD, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses challenges with perioperative immunotherapy in bladder cancer.
Findings from a recent clinical trial showed that the median time to surgery is 7 days in patients with bladder cancer, says Gupta. However, there are no data to inform whether 7 days is too small a window between neoadjuvant therapy, surgery, and postoperative therapy.
However, multidisciplinary care of these patients is paramount to ensure surgeons are aware of potential complications and prior treatments, Gupta explains.
Amidst the ongoing coronavirus disease 2019 (COVID-19) pandemic, developing a greater understanding of the pulmonary toxicities associated with immunotherapeutic agents is important. Moreover, it has become increasingly difficult to pinpoint whether pulmonary adverse effects are immunotherapy-related or COVID-19–related, Gupta concludes.
